# Biofrontera Inc.

**BFRI**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001858685

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $28.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Jul 22, 2026<br>106 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $0.92<br>2026-11-04; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 19, 2026*

We are a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy ("PDT"). The Company's products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamp series (together, the "RhodoLED Lamps"), are used for the treatment of actinic keratosis ("AK"), a common skin condition characterized by the growth of pre-cancerous lesions (or "AKs"). With our national commercial team, we generate revenue by selling our products directly to dermatology offices and groups.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 92.1** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | 11.2% | (6.6%) | 92.1 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 75.3** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |
| Altman Z double-prime | (15.24) | (0.35) | 69.9 | 746 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 1.52x | 2.92x | 80.7 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 61.8** | | | | | |
| Revenue growth, three-year compound | 13.3% | 10.1% | 43.4 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | (17.5%) | 2.2% | 80.1 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-04 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (1.8%) | (2.2%) | 50 |
| Distance from 52-week high | (43.9%) | (26.8%) | 32 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | not computable | (0.9%) | |
| Book value to price | not computable | 0.27 | |
| Sales to price | not computable | 0.28 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (0.19) | (0.19) | 50 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $4.7M |
| Operating cash flow, four quarters | -$7.9M |
| Months of runway | 7.1 |
| Days since last periodic filing | 84 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $412,121 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$10.5M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$13.4M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 3 | assets | us-gaap:Assets | $28.6M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 4 | assets | us-gaap:Assets | $22.1M | 2024-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 5 | current assets | us-gaap:AssetsCurrent | $18.1M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $11.9M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$127.9M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$11.3M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 9 | book equity | us-gaap:StockholdersEquity | $10.5M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 10 | liabilities | us-gaap:Liabilities | $18.1M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$22.7M | 2023-12-31 | 2025-03-20 | 10-K | 25-011052 |
| 12 | interest expense | us-gaap:InterestExpense | $220,000 | 2023-12-31 | 2024-03-15 | 10-K | 24-010133 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $41.7M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37.3M | 2024-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $34.1M | 2023-12-31 | 2025-03-20 | 10-K | 25-011052 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $28.7M | 2022-12-31 | 2024-03-15 | 10-K | 24-010133 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2,000 | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 18 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $138,000 | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 19 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$10.5M | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 20 | income tax | us-gaap:IncomeTaxExpenseBenefit | $25,000 | 2025-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 21 | current assets | us-gaap:AssetsCurrent | $20.7M | 2024-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 22 | current liabilities | us-gaap:LiabilitiesCurrent | $12.0M | 2024-12-31 | 2026-03-19 | 10-K | 26-011625 |
| 23 | assets | us-gaap:Assets | $27.9M | 2023-12-31 | 2025-03-20 | 10-K | 25-011052 |
| 24 | assets | us-gaap:Assets | $50.9M | 2022-12-31 | 2024-03-15 | 10-K | 24-010133 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.